Apyx Medical Expands AYON System with FDA-Cleared Power Liposuction
Event summary
- Apyx Medical received expanded FDA 510(k) clearance for its AYON Body Contouring System to include power liposuction on May 11, 2026.
- The new capability uses a reciprocating cannula to enhance fat removal efficiency and reduce surgeon effort.
- AYON is the first system to integrate fat removal, closed-loop contouring, and Renuvion tissue contraction in a single platform.
- The company filed for the label expansion in October 2025 and plans a limited commercial launch before scaling adoption.
The big picture
The FDA clearance positions AYON as a comprehensive body contouring platform, consolidating multiple modalities into one system. This aligns with broader industry trends toward integrated surgical solutions that improve workflow efficiency and patient outcomes. The strategic move could strengthen Apyx Medical's leadership in surgical aesthetics, particularly as demand for minimally invasive procedures grows.
What we're watching
- Adoption Pace
- How quickly surgeons will adopt the power liposuction function after the limited commercial launch.
- Competitive Response
- Whether competitors will introduce similar integrated systems to challenge AYON's position.
- Revenue Impact
- The extent to which the expanded capabilities will drive AYON's return on investment and market penetration.
Related topics